Complication Risk Differs by Subtype
Reviewed by CDE Mehandi Sharma · Updated
This is the clearest example of why the subtype matters more than the word diabetes, and the numbers are striking.
A UK comparison measured complication rates in GCK-MODY against Type 2 diabetes:
| GCK-MODY | Type 2 diabetes | |
|---|---|---|
| Microvascular (eyes, kidneys, nerves) | 1% | 36% |
| Macrovascular (heart, stroke, circulation) | 4% | 30% |
That is a very large difference, and it is consistent with the mechanism: GCK-MODY produces mild, stable, non-progressive hyperglycaemia around a slightly raised set point, rather than the sustained and worsening exposure that drives damage in Type 2 diabetes.
The progressive subtypes are different. HNF1A and HNF4A-MODY involve declining beta-cell function and worsening glucose control over time, so they carry the complication risks of ordinary diabetes and need the corresponding screening.
HNF1B is different again, because it affects the kidneys directly through the gene rather than through glucose.
So the practical conclusion is not that monogenic diabetes is benign. It is that your screening schedule should follow your gene, and that applying Type 2 assumptions to GCK-MODY overstates the risk while applying GCK assumptions to a progressive subtype understates it.
Ask which applies to you specifically.